Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Dachs1on May 28, 2016 5:19am
293 Views
Post# 24912595

RE:A poker game...

RE:A poker game...thank you - very good posting. 

I believe the deadline for 1067 and Wanbang is still valid.
the latest news was a little spongy but i would not overrate what a company present on such conferences. On such events it more about to show how good the company and the technolgy is and 1067 is at the far advanced (safty tests, etc.) vs. other cosmetics compounds (Anti aging...)



“As part of due diligence of a third party, our CRO performed additional safety and‎ efficacy studies with our innovative skin lightening compound SBM-TFC-1067 in the last several weeks. The results are a major milestone that will significantly help us to close a licensing deal for this new compound in due course.


“In anticipation of a near-term upfront payment as part of a licensing agreement for our novel skin lightening compound, we are increasing our research activities substantially,” reports Dr. Howard Verrico, Chairman and CEO of Sirona Biochem.

As you know i still have Allergan (next Amorepacific, L'Oreal) top on the list. Why should Allergan now do yet a deal before TEVA deal is settled?  

Good month to go till Q2/16 is history.

Have a nice weekend
Dachs


 


I suppose that now fluttering nerves of many investors .
Bullboard Posts